Led · Series B · Jul 2023

Proclaim builds the Custom-Jet Oral Health System: a 3D-printed, personalized mouthpiece paired with a hydro station that pulses 60 jets of pressurized water over seven seconds. The system is intended to be used alongside regular brushing and is clinically claimed to be 10× more effective at reducing gum bleeding, nearly 13× more effective at reducing gum inflammation, and almost 8× more effective at reducing plaque versus daily brushing and string flossing. Each mouthpiece is customized to an individual’s anatomy to target plaque and bacteria precisely. Proclaim raised $15 million in a Series B to fund initial commercialization and scale awareness and education among dental professionals and consumers. CEO Heberto Calves said the round is meant to set the stage for a growth C round in Q3 2024. The company positions the product as an at-home oral-health platform that could also help address broader systemic health issues linked to gum disease.

Led · Seed · Oct 2022

Oma Fertility aims to improve in‑vitro fertilization by combining better technology with respectful care and ethical pricing. The company was founded by Gurjeet Singh in 2020. Oma has raised $71.5 million across three funding rounds. Chrissy Meyer and Root Ventures invested in the last two rounds. The company is actively engaging in public outreach—its founder and an investor are scheduled to speak at a TechCrunch Live event. The articles emphasize its mission to make IVF more accessible and patient‑centered. Oma Fertility combines artificial intelligence and robotics with clinical care to reduce the cost and human error associated with IVF. Its initial product, Oma Sperm InSight™, uses AI to identify the most promising sperm cells to improve embryo quality and boost success rates. The company opened its first clinic in Santa Barbara, California in 2021 and announced plans to expand nationally through 2023. Co-founder and CCO Dr. Sahil Gupta previously founded the Aveya clinic chain in India and Nepal and brought demonstrated operational experience to the venture. Oma positions a team of engineers and physicians together to automate manual lab tasks and standardize assessments where embryologists historically disagree. The company markets its approach as making fertility treatments more accessible and affordable compared with typical U.S. IVF pricing.

Participated · Seed · Sep 2022

Willow Servicing is a San Francisco-based cloud mortgage servicing platform that automates routine servicing tasks and compliance. Led by founder and CEO Laura Cain, the platform was originally designed to manage the first few payments on a loan but quickly expanded to support additional loan types and processes. It now supports HELOCs, construction loans, and handles appraisal and payoff fees. Since launching earlier this year, the company has serviced $750M in loans. Willow intends to use the funds from the recent round to expand operations and broaden its business reach.

Participated · Equity · Apr 2014

Isarna Therapeutics is a leader in TGF-β therapeutics developing inhibitors intended to stimulate the human immune system to fight cancer and other diseases. The company is advancing a pipeline of novel oligonucleotides and combination modalities aimed at transcending clinical response and improving patient outcomes. Isarna announced it raised €5.5M (US$7.6M) in equity from current investors including AT NewTec, Global Asset Funds, and MIG Fonds. It also named Elizabeth Czerepak as Chief Financial Officer and Chief Business Officer to lead a new New York City office. Management described the hire and U.S. expansion as key strategic steps toward building the company’s presence in the global biotech industry. The company lists headquarters in Munich and a U.S. address on Madison Avenue in New York. Isarna Therapeutics is a Munich, Germany-based company that develops TGF-β inhibitors to fight cancer. Its core programs are oligonucleotide candidates designed to inhibit various isoforms of TGF-β, a pathway implicated in tumor immune evasion and proliferation. The company raised €13m (US$17.8m) in equity to advance this pipeline. Backers included new private investor AT NewTec and existing MIG-managed funds. Isarna is led by CEO Dr. Philippe Calais and intends to use the proceeds to push development of its oligonucleotide portfolio.